PROM1 and hepatocellular carcinoma: The development of effective treatments for HCC has been hindered by the enhanced expression of the CSCs marker CD133, which has been reported to be aberrantly regulated by abnormal inflammatory factors, such as IL-6/STAT3, and effector immune cells.